Virtus LifeSci Biotech Clinical Trials ETF (ARCA: BBC)

Dernières nouvelles pour Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC)

Virtus LifeSci Biotech Clinical Trials ETF

Healthcare

Other

Financial Services

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Avidity Biosciences Inc

Summit Therapeutics Plc Spon Adr

Viking Therapeutics Inc Com

Cullinan Oncology Inc

Dyne Therapeutics Inc

Novavax Inc

Vera Therapeutics Inc Ser C Pc Pp

Spyre Therapeutics Inc

Merus Nv

Arcellx, Inc.

Belite Bio, Inc

Acelyrin Inc

Newamsterdam Pharma Company Nv

Mineralys Therapeutics Inc

Neumora Therapeu

Structure Therapeutics Inc ADR USD.0001

Neurogene Inc - Series B

Prime Medicine, Inc.

Akero Therapeutics Inc

Liquidia Technologies Inc

Sana Biotechnology Inc

Arcutis Biotherapeutics Inc

Anaptysbio Inc

Xeris Pharmaceuticals Inc Com

Vir Biotechnology Inc

89bio Inc

Soleno Therapeutics Inc

Protagonist Therapeutics Inc

JPMorgan BetaBuilders Canada ETF

JPMorgan BetaBuilders USD Investment Grade Corporate Bond ETF

Blackbird Critical Metals Corp

BLACKBIRD CRTICL METALS by BLACKBIRD CRITICAL METALS CORP.

Concrete Pumping Holdings, Inc. - Common Stock

Concrete Pumping Holdings Inc

Concrete Pumping Holdings Inc Warrants(06/12/2023)

Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares are surging Wednesday after the company announced an expansion of its multi-domain Family of Systems to maritime platforms. Red Cat is due to report earnings after the bell. Here&#8217;s what you <a href="https://www.benzinga.com/pressreleases/25/05/g45401620/red-cat-expands-maritime-domain-capabilities-with-battle-tested-unmanned-surface-vessels">need to know</a>.
What Happened: Red Cat introduced a new line of unmanned surface vessels, marking the company&#8217;s official entry into the maritime autonomy market. 
Red Cat said it aims to be a provider of comprehensive, interoperable unmanned systems for air, land and sea operations and highlighted its existing partnership with Ocean Power Technologies, which is focused on integrating the company&#8217;s aerial drones with autonomous maritime platforms.
Red Cat said it decided to introduce its own line of kinetic-capable Unmanned Surface Vessels (USVs) in direct response to rising geopolitical tensions and a shift in U.S. defense priorities.
&#8220;This is a pivotal moment for Red Cat as we evolve from an aerial-first drone company into a true multi-domain defense provider. This expansion into maritime platforms opens significant opportunities in a fast-growing and urgently needed defense sector,&#8221; said Jeff Thompson, CEO of Red Cat.
Red Cat noted that its USV technology already has more than 10,000 hours of operating time in live combat missions.&nbsp;The company plans to start production of a multi-role craft developed for maritime operations in the third quarter, which will offer larger payload capabilities, extended endurance and more firepower.
Red Cat is scheduled to report <a href="https://www.benzinga.com/calendars/earnings">first-quarter financial results</a> after the market close on Wednesday. The company is expected to report a loss of 10 cents per share and revenue of $2.4 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
RCAT Price Action: <a href="http://benzinga.com/quote/rcat">Red Cat shares</a> were up 5.49% at $6.73 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45389449/4-tech-stocks-with-huge-earnings-momentum">4 Tech Stocks With Huge Earnings Momentum</a></li>
</ul>
Photo: katjen/Shutterstock.

News

Movers

RCAT

Red Cat Holdings Stock Is Ripping Higher Wednesday: What's Going On?

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

AGRI

AGRIForce Announces Delivery Of 500 Bitmain S19j Pro 100T Bitcoin Mining Machines To Its EPCM Contractor For Installation At East Palestine, Ohio Bitcoin Mining Site

FirstCash Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) is expanding into the U.K. with the <a href="https://www.benzinga.com/pressreleases/25/05/g45398582/firstcash-to-acquire-h-t-group-the-leading-operator-of-pawnshops-in-the-united-kingdom" target="_blank" rel="noreferrer noopener">acquisition</a> of H&amp;T Group plc, the country&#8217;s largest pawnbroker chain.
The Texas-based pawnshop operator announced on Wednesday it will purchase all outstanding H&amp;T shares through its U.K. subsidiary, Chess Bidco Limited, in an all-cash deal valued at approximately $394 million.
The agreement includes a payment of 650 pence per share and a final dividend of 11 pence per share, payable in late June. The acquisition strengthens FirstCash&#8217;s global footprint, adding 285 U.K. stores to its existing network and positioning the company as the largest publicly traded pawn operator across the U.S., Latin America, and the U.K.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" rel="noreferrer noopener">Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii&#8217;s Plavix Lawsuit</a>
FirstCash CEO and Vice-Chairman Rick Wessel said the acquisition aligns with the company&#8217;s long-term strategy and praised H&amp;T&#8217;s strong brand and experienced leadership. H&amp;T CEO Chris Gillespie called the deal a testament to the company&#8217;s success and a new chapter for growth under FirstCash&#8217;s ownership.
Beyond geographic expansion, FirstCash expects to benefit from operational efficiencies and scale. The company anticipates the acquisition will boost earnings per share and EBITDA, supporting its broader international strategy.
Upon completion, the combined business will operate more than 3,000 pawn locations worldwide, with the potential for further expansion into additional European markets.
FirstCash held cash and cash equivalents of <a href="https://www.benzinga.com/pressreleases/25/01/g43330177/firstcash-reports-record-fourth-quarter-and-full-year-operating-results-accelerating-pawn-demand-d" target="_blank" rel="noreferrer noopener">$175.095 million</a> as of December 31, 2024.
Price Action: FCFS stock is down 2.14% to $129.91 premarket at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45389449/4-tech-stocks-with-huge-earnings-momentum" target="_blank" rel="noreferrer noopener">4 Tech Stocks With Huge Earnings Momentum</a></li>
</ul>
Image by PeopleImages.com &#8211; Yuri A via Shutterstock

FCFS

FirstCash Enters UK Market With $394 Million Acquisition Of H&T Group

Macro Notification

WIIM

General

AMD shares are trading higher after the company's board approved a new $6 billion share repurchase program.

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) smashed through <a href="https://www.benzinga.com/quote/PLTR/news">a major milestone</a> Tuesday, topping a $300 billion market cap for the first time ever after hitting an all-time high of $130.60 during the session.
That's not a typo. Just two years ago, Palantir's valuation sat at $20 billion. One year ago? $49 billion. Now? A staggering $302.3 billion &#8211; nearly an eightfold increase in just 24 months. The AI-driven defense tech firm is now one of Wall Street's most explosive comeback stories.
<h2 class="wp-block-heading">Behind The Cocktail Of Bullish PLTR Stock Technicals</h2>
PLTR stock has surged 497% over the past year, including a 70% rally in 2025 alone and a 38% jump in just the past month. Behind the momentum is a cocktail of bullish technicals, AI-driven optimism, and some headline-grabbing confidence from CEO Alex Karp.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080927/Screenshot-2025-05-14-at-5.39.17-PM.png" alt="" class="wp-image-914888" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080927/Screenshot-2025-05-14-at-5.39.17-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080927/Screenshot-2025-05-14-at-5.39.17-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, PLTR stock is firing on all cylinders. It trades above its eight, 20, 50, and 200-day simple moving averages. The Relative Strength Index (RSI) of 68.11 points to healthy bullish momentum without being overbought, while a Moving Average Convergence Divergence (MACD) indicator of 8.38 confirms strong buying pressure.
Read Also: <a href="https://www.benzinga.com/25/05/45358811/tech-traders-are-speed-dating-volatility-and-palantirs-the-perfect-case-study">Tech Traders Are Speed-Dating Volatility And Palantir Is The Perfect Case Study</a>
<h2 class="wp-block-heading">Saudi = Engineering Excellence, While Europeans Have Given Up</h2>
Speaking at the Saudi-U.S. Investment Forum on Tuesday, Karp lavished <a href="https://www.msn.com/en-us/money/companies/palantir-ceo-alex-karp-praises-saudi-engineers-and-takes-a-swipe-at-europe-saying-it-has-given-up-on-ai/ar-AA1EJoqW">praise</a> on Saudi engineers for their &#8220;engineering excellence&#8221; and forward-looking approach to AI. He didn't mince words about the other side of the Atlantic either. "Europe, where, you know, it&#8217;s like people have given up," Karp said, highlighting the continent's sluggish AI adoption and over-regulation.
The comments, made as President Donald Trump and a cadre of U.S. tech executives arrived in Riyadh, reinforced Palantir's growing presence in global AI conversations &#8211; particularly in geopolitically strategic regions like the Middle East.
Karp's bold bets, both strategic and rhetorical, are paying off. And as Palantir crosses into mega-cap territory, the message to skeptics is clear &#8211; AI is war tech, and Palantir intends to lead both fronts.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45396297/cathie-wood-dumps-palantir-as-stock-touches-peak-prices-bails-on-soaring-flying-taxi-maker-archer-aviation">Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

Trading Ideas

PLTR

Palantir Storms Past $300 Billion Valuation, CEO Karp Champions Saudi AI Over Europe

AFRM

Affirm Named Pay-Over-Time Provider For Costco.com In The US

LUXE

LuxExperience shares are trading higher after the company reported Q3 financial results and beat its adjusted EPS and revenue estimates.

The launch of the Melania (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MELANIA</a>) meme coin, tied to former First Lady Melania Trump, has stirred controversy following a series of unusually timed trades that suggest some investors had early access <a href="https://www.benzinga.com/markets/25/05/45298198/report-melania-trump-memecoin-insiders-made-100m-front-running-launch">before its official debut</a>.
What Happened: Within minutes of the token's quiet creation and prior to any public acknowledgment by Melania Trump on Truth Social, 24 crypto wallets purchased $2.6 million worth of MELANIA, the Financial Times <a href="https://www.ft.com/content/7782f730-3ff2-4a8e-a071-5de8536d382e?accessToken=zwAAAZbLrhmUkc93gvcwP_JKjtOgcV3oU204Lg.MEQCICf_hwEt9GB34jzzmbVUVluLVDAW7E3tAZGPGAxgMlkIAiAr-Ias_6612CaqaPlq6520Xk7dKgXgcu2XYATTSCQDWA&amp;segmentId=e95a9ae7-622c-6235-5f87-51e412b47e97&amp;shareType=enterprise&amp;shareId=e783a726-85ff-4e77-8360-a65a16b00676">reported</a> on Monday.
Just days later, those same wallets offloaded their positions for a staggering $100 million in profits. 
The speed, scale and timing of these trades raise serious concerns over how information was distributed ahead of launch.
Meme coins, unlike traditional IPOs, are often priced near zero initially and allowed to find market value. 
This dynamic attracts opportunists known as "snipers," who attempt to buy in early and dump when prices surge. 
As one project organizer, Hayden Davis, acknowledged in a separate interview, "Every launch this happens… where it's like three to ten guys get these massive chunks."
Davis, who had previously been associated with the ill-fated LIBRA coin, claimed that no members of the MELANIA team profited from the launch. However, he has not responded to direct questions about this project.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45384651/bitcoin-rally-is-in-a-high-risk-high-reward-zone-glassnode">Bitcoin Rally Is In A &#8216;High-Risk, High-Reward&#8217; Zone: Glassnode</a>
Why It Matters: In contrast, the launch of the Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) token, endorsed by Donald Trump, appeared more structured.
No early access was permitted, and preparations began weeks in advance. 
The token's promotional website was registered nearly a month before launch, and liquidity was added to its trading pool well ahead of Trump's official announcement.
The MELANIA launch, by comparison, was far more chaotic.
The domain melaniameme.com was only registered the day of the launch. 
The token itself was created just 78 minutes before the announcement, and trading liquidity was funded less than an hour before Melania&#8217;s post went live.
Despite both tokens having identical supply structures, one billion tokens, with 20% released initially, the on-chain data paints a different picture. 
TRUMP&#8217;s remaining 800 million tokens were clearly sent to a reserve address, easily tracked on the blockchain.
For MELANIA, the tokens are dispersed across numerous accounts, making auditing and verification significantly more difficult.
While meme coins inherently lack the regulation and oversight of traditional securities, the disparity in how these two Trump-themed tokens were launched raises broader concerns about transparency, fairness, and the potential for misuse, especially when tied to political figures with significant influence.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45380119/solana-faces-competition-from-sui-ton-base-blockchains-report">Solana Faces Competition From Sui, Ton, Base Blockchains: Report</a></li>
</ul>
Image: Shutterstock

$MELANIA

$TRUMP

The Curious Story Behind The Melania Trump Meme Coin Launch

<a href="https://www.amd.com/">AMD</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) today announced that its board of directors approved a new $6 billion share repurchase program. The new authorization is in addition to the remaining balance, as of March 29, 2025, of approximately $4 billion of its existing share repurchase program, increasing the total current repurchase authority to approximately $10 billion.

Buybacks

AMD Announces New $6B Share Repurchase Authorization; New Authorization Is In Addition To The Remaining Balance, As Of March 29, 2025, Of 
 ~$4B Of Its Existing Share Repurchase Program, Increasing The Total Current Repurchase Authority To ~$10B

During the last three months, 10 analysts shared their evaluations of AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along with a high estimate of $250.00 and a low estimate of $194.00. Marking an increase of 1.52%, the current average surpasses the previous average price target of $216.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747227667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of AbbVie's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$216.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$214.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$241.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$194.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into AbbVie's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AbbVie analyst ratings.</a>
<h2>About AbbVie</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>A Deep Dive into AbbVie's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: AbbVie's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 8.39%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 9.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AbbVie's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 53.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA stands out, surpassing industry averages. With an impressive ROA of 0.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 49.22, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ABBV

Expert Outlook: AbbVie Through The Eyes Of 10 Analysts

SMWB

Similarweb shares are trading lower after the company reported a Q1 adjusted EPS miss.

4 analysts have shared their evaluations of Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $97.25, a high estimate of $115.00, and a low estimate of $84.00. A 18.5% drop is evident in the current average compared to the previous average price target of $119.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1747227660_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Merck &amp; Co among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merck &amp; Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Merck &amp; Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MRK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merck &amp; Co analyst ratings.</a>
<h2>About Merck &amp; Co</h2>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Merck &amp; Co: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Merck &amp; Co faced challenges, resulting in a decline of approximately -1.56% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Merck &amp; Co's net margin is impressive, surpassing industry averages. With a net margin of 32.71%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merck &amp; Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merck &amp; Co's ROA stands out, surpassing industry averages. With an impressive ROA of 4.37%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.72.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Merck & Co: Insights From 4 Financial Analysts

SkyWest's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NYSE">SKYW</a>) short percent of float has risen 4.99% since its last report. The company recently reported that it has 1.32 million shares sold short, which is 4.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SkyWest Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747227631_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SkyWest has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SkyWest's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SkyWest's peer group average for short interest as a percentage of float is 8.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SKYW

Is SkyWest Gaining or Losing Market Support?

Analysts' ratings for Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $103.45, a high estimate of $120.00, and a low estimate of $90.00. Surpassing the previous average price target of $100.20, the current average has increased by 3.24%.
<img src="https://www.benzinga.com/files/images/story/2025/1747227626_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Consolidated Edison by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$114.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Shahriar Pourreza</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>William Appicelli</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>William Appicelli</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Weisel</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Consolidated Edison. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Consolidated Edison compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Consolidated Edison's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Consolidated Edison's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Consolidated Edison analyst ratings.</a>
<h2>Unveiling the Story Behind Consolidated Edison</h2>
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange &amp; Rockland, or O&amp;R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York - including New York City and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
<h3>Consolidated Edison: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Consolidated Edison displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 12.1%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Consolidated Edison's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Consolidated Edison's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.46%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Consolidated Edison's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Consolidated Edison's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Consolidated Edison Stock: Analyst Perspectives (11 Ratings)

Intercontinental Exchange's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) short percent of float has fallen 4.21% since its last report. The company recently reported that it has 5.17 million shares sold short, which is 0.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Intercontinental Exchange Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747227625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intercontinental Exchange has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Intercontinental Exchange's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Intercontinental Exchange's peer group average for short interest as a percentage of float is 4.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Intercontinental Exchange's Recent Short Interest

Idacorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) short percent of float has fallen 6.88% since its last report. The company recently reported that it has 1.48 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Idacorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747227619_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Idacorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Idacorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Idacorp's peer group average for short interest as a percentage of float is 2.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Idacorp?

XAGEW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Keybanc analyst Sophie Karp downgrades Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Sector Weight to Underweight and announces $78 price target.

Downgrades

Price Target

Keybanc Downgrades Southern to Underweight, Announces $78 Price Target

ABSI

Absci shares are trading higher after the company announced it began dosing the first participants in its Phase 1 ABS-101 clinical trial.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Mike Matson upgraded the rating for Establishment Labs Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announced a $48 price target. Establishment Labs shares closed at $34.96 on Tuesday. <a href="https://www.benzinga.com/quote/esta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Ashley Helgans upgraded PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Hold to Buy and raised the price target from $70 to $105. PVH shares closed at $80.50 on Tuesday. <a href="https://www.benzinga.com/quote/pvh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Neutral to Buy and raised the price target from $600 to $700. Regeneron Pharmaceuticals shares closed at $574.16 on Tuesday. <a href="https://www.benzinga.com/quote/regn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stan Berenshteyn upgraded the rating for Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raised the price target from $31 to $35. Omnicell shares closed at $28.00 on Tuesday. <a href="https://www.benzinga.com/quote/omcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp upgraded the rating for Ameren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sector Weight to Overweight and announced a $103 price target. Ameren shares closed at $94.32 on Tuesday. <a href="https://www.benzinga.com/quote/aee/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PVH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png" alt="" class="wp-image-914981" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Comments

Virtus LifeSci Biotech Clinical Trials ETF

Actualités

Dernières nouvelles pour Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL